Allergan To Acquire Motus, To Initiate Phase 3 Trials Of Relamorelin

(RTTNews) - Allergan plc (AGN), and Rhythm Holding Company, LLC, which owns Motus Therapeutics, announced the top line results of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Motus' ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes. The companies said the clinical results were very encouraging. Based on these results and the results observed in the earlier phase 2a trial, Allergan has exercised its option to acquire Motus Therapeutics and intends to initiate Phase 3 clinical trials of relamorelin.

David Nicholson, Executive Vice President of Global Research and Development for Allergan, said: "We very much look forward to sharing this phase 2b data with the US Food and Drug Administration and to discussing our plans to conduct Phase 3 trials."